Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis

• Authors: Madhusmita Behera, Emory University; Taofeek K Owonikoko, Emory University; Zhengjia Chen, Emory University; Scott A. Kono, Emory University; Fadlo Khuri, Emory University; Chandra P. Belani, Penn State Hershey Cancer Institute; Suresh S Ramalingam, Emory University
• Journal Title: Lung Cancer
• Volume: Volume 77, Number 2
• Publisher: Elsevier: 12 months | 2012-08, Pages 331-338
• Type of Work: Article | Post-print: After Peer Review
• Publisher DOI: http://doi.org/10.1016/j.lungcan.2012.03.019
• Subjects: Health Sciences, Oncology
• Keywords: Maintenance therapy; non-small cell lung cancer; NSCLC; EGFR; pemetrexed; erlotinib; gefitinib

Abstract

Background Maintenance therapy is a new treatment paradigm for advanced non-small cell lung cancer (NSCLC). We conducted a meta-analysis of randomized studies with single agent maintenance therapy. Methods An electronic literature search of public databases (MEDLINE, EMBASE, Cochrane library) and manual search of relevant conference proceedings was performed. A formal meta-analysis was conducted using Comprehensive Meta Analysis software (Version 2.0). Outcome data were pooled and reported as hazard ratio (HR). The primary outcome of interest was overall survival (OS) and secondary outcome was progression free survival (PFS). Results Twelve studies were included (5 meeting abstracts, 7 full manuscripts) with a total of 4286 patients (maintenance arm/control arm- 2449/1837, median age 61 years, males -69 %). The OS (HR 0.86, 95% confidence intervals [CI] 0.80-0.92; P=0.0003) and PFS (HR 0.80, 95% CI 0.77-0.84; P<0.0001) were superior with maintenance therapy. ‘Switch’ maintenance was associated with significant OS and PFS improvement (OS HR 0.84, 95% CI 0.77-0.91; P=0.00026; PFS HR 0.62, 95% CI 0.57-0.67; P<0.0001). Despite a modest improvement in PFS (HR 0.90, 95%CI 0.85-0.95; P=0.007), “continuation” maintenance was not associated with survival benefit (HR 0.927, 95%CI 0.78-1.09; P=0.33). Improvements in OS and PFS were observed with both EGFR-targeted agents (HR 0.83, 95% CI 0.74-0.92; P=0.004; HR 0.64, 95% CI 0.58-0.71 P<0.0001) and cytotoxic agents (HR 0.89, 95% CI 0.80-0.98; P=0.018; HR 0.85, 95% CI 0.80-0.89; P < 0.0001). Conclusions Single agent maintenance therapy improves overall survival, though statistical significance was only noted with ‘switch’ maintenance.